Statin use and Parkinson's disease in Denmark

Movement Disorders

Volumn 25, Issue 9, 2010, Pages 1210-1216

  Ritz, Beate ^a   Manthripragada, Angelika D ^a   Qian, Lei ^a   Schernhammer, Eva ^b   Wermuth, Lene ^c   Olsen, Jorgen ^d   Friis, Soren ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

Parkinson's disease; Pharmacy; Pharmocoepidemiology; Record study; Statin use

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; ASSOCIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DENMARK; DRUG MECHANISM; DRUG USE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; FACTUAL DATABASE; MIDDLE AGED; REGISTER; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DENMARK; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PRESCRIPTION DRUGS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 77955067166     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23102     Document Type: Article

References (32)

1. Pfeiffer RF. Nonmotor parkinsonism. Parkinsonism Relat Disord 2007;13 (Suppl 3):S211-S220.
2. Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005;57:561-569.
3. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53 (Suppl 3):S49-S58; discussion S58-S60.
4. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600-609.
5. Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 2008;44:1787-1794.
6. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002;23:1908-1921. (Pubitemid 35448549)
7. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001;187:81-89.
8. Bar-On P, Crews L, Koob AO. Statins reduce neuronal alphasynuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 2008;105:1656-1667. (Pubitemid 351678486)
9. Wolozin B, Wang SW, Li NC. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
10. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008;70:1418-1422.
11. Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 2008;31:399-407. (Pubitemid 351563732)
12. Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 2008;15:1272-1273.
13. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69:1688-1695. (Pubitemid 350287125)
14. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70:1972-1979.
15. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
16. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-448.
17. World Health Organization Collaborating Centre for Drug Statistics Methodology ATC Classification Index with DDDs Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology, 2003.
18. Charlson ME, Sax FL, Mackenzie CR. Morbidity during hospitalization: can we predict it? J Chronic Dis 1987;40:705-712.
19. Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993;267:1085-1090. (Pubitemid 24068669)
20. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005;1037:1-6.
21. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-2679. (Pubitemid 28007534)
22. Singh S, Das T, Ravindran A. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Rep 2005;10:103-109.
23. Levecque C, Elbaz A, Clavel J. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum Mol Genet 2003;12:79-86.
24. Huerta C, Sanchez-Ferrero E, Coto E. No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neurosci Lett 2007;413:202-205. (Pubitemid 46209509)
25. Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 2008;9:249-262.
26. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-S144.
27. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003;18:101-111.
28. Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, coenzyme Q10, and Parkinson's disease. Parkinsonism Relat Disord 2005;11:81-84.
29. Huang X, Chen H, Miller WC. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007;22:377-381.
30. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998-1002. (Pubitemid 44729842)
31. De Lau LM, Stricker BH, Breteler MM. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 2007;22:1985.
32. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008;23:1013-1018.